SCHEMBL25813827

SCHEMBL25813827

Cc1[nH]c2ccc(C(=O)N(C)CCN(C)C)cc2c1C

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
THRB P10828 1/20 0.58
HPGD P15428 1/20 0.58
HCRTR1 O43613 1/20 0.56
TLR9 Q9NR96 3/20 0.52
TLR8 Q9NR97 3/20 0.52
TLR7 Q9NYK1 3/20 0.52
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 2/20 0.49
GFER P55789 1/20 0.49
MAPT P10636 9/20 0.48
TP53 P04637 3/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811321 0.85 KDM4E (0.51) KDM4EALDH1A1THRBHPGDHCRTR1
SCHEMBL25811801 0.82 KMT2A (0.61) KDM4EALDH1A1THRBHPGDHCRTR1
SCHEMBL25811987 0.82 KMT2A (0.58) KDM4EALDH1A1THRBHPGDHCRTR1
SCHEMBL25814483 0.79 ALDH1A1 (0.53) KDM4EALDH1A1THRBHPGDHCRTR1
SCHEMBL25811225 0.79 MAPT (0.68) KDM4EALDH1A1THRBHPGDTLR9
SCHEMBL25813335 0.76 TLR8 (0.53) KDM4EALDH1A1HPGDHCRTR1TLR9
SCHEMBL25815092 0.76 KDM4E (0.59) KDM4EALDH1A1TLR9TLR8TLR7
SCHEMBL25813810 0.76 KDM4E (0.56) KDM4EALDH1A1TLR9TLR8TLR7
SCHEMBL2161737 0.75 MAPT (0.50) KDM4EALDH1A1THRBHPGDHCRTR1
SCHEMBL14211006 0.75 KDM4E (0.75) KDM4EALDH1A1THRBHPGDHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KDM4E 1465/4885ALDH1A1 4430/4885THRB 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.